Fresenius Kabi Recalls One Lot of Tyenne (tocilizumab-aazg) for Glass Particles
A single lot of the tocilizumab biosimilar Tyenne 400 mg/20 mL injection is recalled to the user level after glass particulates were found during internal investigation.
📅 Journal publication: Aug 11, 2026·Last updated: Aug 12, 2026
A critical recall of Tyenne due to glass particles.
Glass particles in injectable drugs can cause serious adverse events like organ damage or embolism. Fresenius Kabi recalled Tyenne due to glass particle contamination. Immediate removal from inventory and return of affected lot is necessary. The Tyenne batch recall prevents serious health risks from glass contamination.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.